Bristol-Myers Squibb CoBMY:NYQ

49.46
0.35 / 0.71%
6.67m
21.20%
0.4536
Close in USDToday's changeShares traded1 year changeBeta
As of Apr 17 2014 21:01 BST.Data delayed by at least 15 minutes.

Search 130 articles on Bristol-Myers Squibb Co

Drug groups step up race for new hepatitis C treatments
Forstmann Little eyes $2bn sale of 24 Hour Fitness chain
Bristol-Myers Squibb: side effects
Merck agrees €20m deal to tap into Ablynx's immunotherapy talent
Hepatitis C: Treated - at a price
AstraZeneca strikes deal with UK's Immunocore
General Electric boosts life sciences division with $1.06bn deal
AstraZeneca in $4bn buyout of diabetes venture partner
AstraZeneca: Astra-nomincal
Bayer set to buy Norwegian cancer drugmaker Algeta

Reuters News Service company announcements are delayed by up to one hour.

© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.